Antibiotic resistance is currently one of the most significant public health concerns. The World Health Organization recently identified antimicrobial resistance as one of the three greatest threats facing mankind in the 21st century. Cationic host-defense peptides (HDPs) are small cationic amphiphilic peptides, and are an ancient and vital part of the innate immune system. HDPs play an essential role in the defense against bacterial infections, as they have broad-spectrum activity against both Gram-positive and Gram-negative bacteria. In addition, HDPs may have less probability to develop drug-resistance observed for conventional antibiotic treatment due to the novel mechanism of bacterial membrane disruption. As such, HDPs are potential antibiotics due to their antibacterial function. However, HDPs have significant drawbacks such as susceptibility to enzymatic degradation, low-to-moderate activity and their inconvenient optimization. We have recently developed a new class of sequence-specific peptidomimetics termed a-AApeptides. In addition to their intrinsic advantages including enhanced stability against proteolysis and limitless potential for chemical modification, some potent molecules display broad-spectrum antimicrobial activity, and do not induce apparent resistance in drug-resistant pathogens. Furthermore, they can also modulate immune responses and show strong anti-inflammatory activity. In addition, one lead compound has shown potent in vivo activity against MRSA in mouse model. Our preliminary data suggest that antimicrobial a-AApeptides mimic the global structure, function and mechanism of AMPs. These findings strongly suggest a-AApeptides may be a new approach for antibiotic development. Our long-term goal is to develop a new class of antimicrobial peptidomimetics (cyclic-lipidated a-AApeptides) with novel mechanisms in the treatment of bacterial infectious disease. The objective here is to synthesize, develop and evaluation of more potent analogs of previously designed antimicrobial cyclic-lipidated a-AApeptides. We will first design and synthesize novel analogs of previously designed antimicrobial cyclic-lipidated a-AApeptides. Through structure-function-relationship (SFR) studies, we will identify lead cyclic-lipidated a-AApeptides that have potent and broad-spectrum activity against a panel of clinically- relevant Gram-negative and Gram-positive bacteria. We will then investigate if bacterial membrane disruption is the general bactericidal mechanism of lead cyclic-lipidated a-AApeptides. Finally, we will assess their in vivo efficacy in a mouse model. The work proposed in the aims is significant because it leads to the identification of new class of antibiotics combating emergent antibiotic resistance. The work is innovative because these a-AApeptides resemble the defense mechanisms of HDPs, and have potent broad-spectrum activity. They are amendable for development of a generation of antibiotics with novel mechanisms.

Public Health Relevance

Antimicrobial resistance is a life-threatening public concern. The major goal of this research is to design, synthesize and investigate a new class of antibacterial biomaterials that capture the mechanism of action of host- defense peptides. Thus, a new generation of antibiotics combating antibiotic-resistant bacteria pathogens will be resulted from our work.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
1R01GM112652-01A1
Application #
8961335
Study Section
Biomaterials and Biointerfaces Study Section (BMBI)
Program Officer
Fabian, Miles
Project Start
2015-07-01
Project End
2020-04-30
Budget Start
2015-07-01
Budget End
2016-04-30
Support Year
1
Fiscal Year
2015
Total Cost
Indirect Cost
Name
University of South Florida
Department
Chemistry
Type
Schools of Arts and Sciences
DUNS #
069687242
City
Tampa
State
FL
Country
United States
Zip Code
33612
Bolarinwa, Olapeju; Zhang, Meng; Mulry, Erin et al. (2018) Sulfono-?-AA modified peptides that inhibit HIV-1 fusion. Org Biomol Chem 16:7878-7882
She, Fengyu; Teng, Peng; Peguero-Tejada, Alfredo et al. (2018) De Novo Left-Handed Synthetic Peptidomimetic Foldamers. Angew Chem Int Ed Engl 57:9916-9920
Li, Chunhui; Teng, Peng; Peng, Zhong et al. (2018) Bis-Cyclic Guanidines as a Novel Class of Compounds Potent against Clostridium difficile. ChemMedChem 13:1414-1420
Singh, Sylvia; Nimmagadda, Alekhya; Su, Ma et al. (2018) Lipidated ?/?-AA heterogeneous peptides as antimicrobial agents. Eur J Med Chem 155:398-405
Bolarinwa, Olapeju; Cai, Jianfeng (2018) Developments with investigating descriptors for antimicrobial AApeptides and their derivatives. Expert Opin Drug Discov 13:727-739
Teng, Peng; Li, Chunhui; Peng, Zhong et al. (2018) Facilely accessible quinoline derivatives as potent antibacterial agents. Bioorg Med Chem 26:3573-3579
Su, Ma; Xia, Donglin; Teng, Peng et al. (2017) Membrane-Active Hydantoin Derivatives as Antibiotic Agents. J Med Chem 60:8456-8465
Nimmagadda, Alekhya; Shi, Yan; Cai, Jianfeng (2017) ?-AApeptides as a new strategy for therapeutic development. Curr Med Chem :
Bolarinwa, Olapeju; Nimmagadda, Alekhya; Su, Ma et al. (2017) Structure and Function of AApeptides. Biochemistry 56:445-457
Sui, Hua; Zhao, Jihui; Zhou, Lihong et al. (2017) Tanshinone IIA inhibits ?-catenin/VEGF-mediated angiogenesis by targeting TGF-?1 in normoxic and HIF-1? in hypoxic microenvironments in human colorectal cancer. Cancer Lett 403:86-97

Showing the most recent 10 out of 26 publications